why choose us

First received: May 10, 2023

Clinical Trial: A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Diffuse Large B-Cell Lymphoma

Study Type: INTERVENTIONAL


Official Title: A PHASE 1b/2, OPEN-LABEL STUDY OF PF-07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED, SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA

Brief Summary: The purpose of this study is to learn about the effects of two study medicines (maplirpacept [PF-07901801] and glofitamab) when given together for the treatment of diffuse large B-cell lymphoma (DLBCL) that is relapsed or is refractory.Relapsed means has returned after last treatment.Refractory means that it has not responded to last treatment.The two study medicines are given after a single dose of obinutuzumab which is the third study medicine.DLBCL is a type of non-Hodgkin lymphoma (NHL).NHL is a cancer of the…

Read more